Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Neurocrine Biosciences, Inc. - Common Stock (NQ:NBIX)

141.65 -0.05 (-0.04%)
Streaming Delayed Price Updated: 11:10 AM EST, Dec 18, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 181,722
Open 141.78
Bid (Size) 141.45 (500)
Ask (Size) 141.85 (300)
Prev. Close 141.70
Today's Range 141.23 - 142.51
52wk Range 84.23 - 160.18
Shares Outstanding 99,700,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Neurocrine Biosciences Inc (NASDAQ:NBIX) Offers a Prime Example of Growth at a Reasonable Price ↗
Neurocrine Biosciences exemplifies GARP investing, blending strong earnings growth, solid profitability, and a reasonable stock price within its sector. 
Via Chartmill
News headline image
Neurocrine Biosciences Inc (NASDAQ:NBIX) Combines Strong Fundamentals with Bullish Technical Setup ↗
Neurocrine Biosciences (NBIX) combines strong growth, high profitability, and a positive technical breakout setup in the neuroscience sector. 
Via Chartmill

Performance

YTD
+2.7%
+2.7%
1 Month
-1.3%
-1.3%
3 Month
-0.8%
-0.8%
6 Month
+11.3%
+11.3%
1 Year
+3.6%
+3.6%

More News

Read More
News headline image
Up 44% Since IPO: Why a Major Fund Just Made a $45 Million Bet on This Digital Health Stock ↗
Via The Motley Fool
Topics Initial Public Offering Regulatory Compliance
News headline image
Acadia Stock Up 59% in a Year — Is a $51 Million New Stake a Bet on a Bigger Rebound? ↗
Via The Motley Fool
News headline image
Earnings Scheduled For October 28, 2025 ↗
Via Benzinga
News headline image
Soleno Turns First Profit on $66 Million in Revenue — Is This Why One Investor Just Made an $87 Million Bet? ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Neurocrine (NBIX) Q3 2025 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
Medicare Slashes Ozempic's Price Tag 71%; Why Novo Nordisk Rallied ↗
Via Investor's Business Daily
Topics Economy Government
News headline image
This Fund Sold $30 Million in PTC Therapeutics Shares Amid a 93% Rally: Here’s Why ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Why This Fund Trimmed a $161 Million Travere Position After a 100% Rally ↗
Via The Motley Fool
News headline image
High Growth Momentum Stock NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) Shows Strong Earnings Acceleration ↗
Via Chartmill
News headline image
Neurocrine's Depression Drug Fails Phase 2 Goal But Shows Encouraging Safety Profile ↗
Via Benzinga
News headline image
Zoom To Rally Around 38%? Here Are 10 Top Analyst Forecasts For Tuesday ↗
Via Benzinga
News headline image
Neurocrine Biosciences Inc (NASDAQ:NBIX) Fits the Affordable Growth Profile ↗
Via Chartmill
News headline image
Neurocrine Biosciences Inc (NASDAQ:NBIX) Presents a Compelling Value Investment Case ↗
Via Chartmill
News headline image
NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) Q3 2025 Earnings Top Estimates, Driving Stock Momentum ↗
Via Chartmill
News headline image
Neurocrine Bio Surges After Crushing Third-Quarter Expectations ↗
Via Investor's Business Daily
News headline image
Examining the Future: Neurocrine Biosciences's Earnings Outlook ↗
Via Benzinga
News headline image
S&P 500 Tops 6,900 Ahead Fed Rate Move, Gold Reclaims $4,000: What's Moving Markets Wednesday? ↗
Via Benzinga
Topics Economy Stocks
News headline image
What 13 Analyst Ratings Have To Say About Neurocrine Biosciences ↗
Via Benzinga
News headline image
Demystifying Neurocrine Biosciences: Insights From 12 Analyst Reviews ↗
Via Benzinga
News headline image
Neurocrine Biosciences Inc (NASDAQ:NBIX) Presents an Affordable Growth Opportunity ↗
Via Chartmill
News headline image
NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) Presents a Compelling Growth and Breakout Opportunity ↗
Via Chartmill
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
Via Benzinga
News headline image
Neurocrine Biosciences Inc (NASDAQ:NBIX): An Affordable Growth Candidate in Biotechnology ↗
Via Chartmill

Frequently Asked Questions

Is Neurocrine Biosciences, Inc. - Common Stock publicly traded?
Yes, Neurocrine Biosciences, Inc. - Common Stock is publicly traded.
What exchange does Neurocrine Biosciences, Inc. - Common Stock trade on?
Neurocrine Biosciences, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Neurocrine Biosciences, Inc. - Common Stock?
The ticker symbol for Neurocrine Biosciences, Inc. - Common Stock is NBIX on the Nasdaq Stock Market
What is the current price of Neurocrine Biosciences, Inc. - Common Stock?
The current price of Neurocrine Biosciences, Inc. - Common Stock is 141.65
When was Neurocrine Biosciences, Inc. - Common Stock last traded?
The last trade of Neurocrine Biosciences, Inc. - Common Stock was at 12/18/25 11:10 AM ET
What is the market capitalization of Neurocrine Biosciences, Inc. - Common Stock?
The market capitalization of Neurocrine Biosciences, Inc. - Common Stock is 14.12B
How many shares of Neurocrine Biosciences, Inc. - Common Stock are outstanding?
Neurocrine Biosciences, Inc. - Common Stock has 14B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.